WHO ICTRP trial
Improving radical resection rates in patients with breast cancer by…
EUCTR2022-002804-19-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2022-002804-19-NL |
|---|---|
| Public title | Improving radical resection rates in patients with breast cancer by intraoperative fluorescence imaging – the MARGIN-2 study |
| Scientific title | Improving radical resection rates in patients with breast cancer by intraoperative imaging using bevacizumab-IRDye800CW – the MARGIN-2 study |
| Primary sponsor | University Medical Center Groningen |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | Female breast cancer patients with small tumor size in which breast conserving therapy is advised by the multidisciplinary tumor board.;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: Bevacizumab Product Name: Bevacizumab-IRDye800CW Product Code: Bevacizumab-IRDye800CW Pharmaceutical Form: Solution for infusion |
| Registration date | Oct 25, 2022 |
| Target size | 60 |
| Secondary IDs | 10975 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: